SCHEMBL3842831

SCHEMBL3842831

COc1c(C)c(C=O)n2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.56
ALDH1A1 P00352 12/20 0.52
KDM4E B2RXH2 8/20 0.52
POLB P06746 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
NPC1 O15118 4/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAPT P10636 6/20 0.41
HTT P42858 2/20 0.40
KMT2A Q03164 7/20 0.37
MEN1 O00255 6/20 0.37
GAA P10253 5/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
L3MBTL1 Q9Y468 3/20 0.36
ATM Q13315 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25775831 0.81 LMNA (0.64) LMNAALDH1A1KDM4EPOLBTDP1
SCHEMBL6220492 0.80 ALDH1A1 (0.43) LMNAALDH1A1KDM4EPOLBTDP1
SCHEMBL7442238 0.79 LMNA (0.44) LMNAALDH1A1KDM4EPOLBTDP1
SCHEMBL4510814 0.77 LMNA (0.59) LMNAALDH1A1KDM4EPOLBTDP1
SCHEMBL19220395 0.74 ALDH1A1 (0.54) LMNAALDH1A1KDM4EPOLBTDP1
SCHEMBL3671567 0.73 LMNA (0.55) LMNAALDH1A1KDM4EPOLBTDP1
SCHEMBL6217317 0.69 ALDH1A1 (0.38) LMNAALDH1A1KDM4ETDP1SMN1; SMN2
SCHEMBL3603667 0.67 HTR6 (0.41) LMNANPC1KMT2AMEN1GAA
SCHEMBL6218948 0.66 HTT (0.51) LMNAALDH1A1KDM4ENPC1SMN1; SMN2
SCHEMBL3608384 0.66 HTT (0.51) LMNAALDH1A1KDM4ENPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1713543-A2 USE OF SUBSTITUTED 1,2,3 INDOLIZINE DERIVATIVES FOR TREATING DISEASES ASSOCIATED WITH A PATHOLOGICAL ANGIOGENESIS Sanofi-Aventis (FR) 2006-10-25 EP claimed
WO-2005082457-A2 USE OF SUBSTITUTED 1,2,3 INDOLIZINE DERIVATIVES FOR TREATING DISEASES ASSOCIATED WITH A PATHOLOGICAL CHOROIDAL ANGIOGENESIS SANOFI-AVENTIS (FR) 2005-09-09 WO claimed
EP-1495023-B1 NOVEL 1,2,3-SUBSTITUTED INDOLIZINE DERIVATIVES, INHIBITORS OF FGFS, METHOD FOR MAKING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI AVENTIS (FR) 2005-09-07 EP claimed
EP-1495023-A1 NOVEL 1,2,3-SUBSTITUTED INDOLIZINE DERIVATIVES, INHIBITORS OF FGFS, METHOD FOR MAKING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Sanofi-Aventis (FR) 2005-01-12 EP claimed
WO-2003084956-A1 NOVEL 1,2,3-SUBSTITUTED INDOLIZINE DERIVATIVES, INHIBITORS OF FGFS, METHOD FOR MAKING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI-AVENTIS (FR) 2003-10-16 WO claimed
EP-1713543-B1 USE OF SUBSTITUTED 1,2,3 INDOLIZINE DERIVATIVES FOR TREATING DISEASES ASSOCIATED WITH A PATHOLOGICAL ANGIOGENESIS SANOFI AVENTIS (FR) 2009-11-11 EP disclosed
EP-1713543-A2 USE OF SUBSTITUTED 1,2,3 INDOLIZINE DERIVATIVES FOR TREATING DISEASES ASSOCIATED WITH A PATHOLOGICAL ANGIOGENESIS Sanofi-Aventis (FR) 2006-10-25 EP disclosed
WO-2005082457-A2 USE OF SUBSTITUTED 1,2,3 INDOLIZINE DERIVATIVES FOR TREATING DISEASES ASSOCIATED WITH A PATHOLOGICAL CHOROIDAL ANGIOGENESIS SANOFI-AVENTIS (FR) 2005-09-09 WO disclosed
EP-1495023-B1 NOVEL 1,2,3-SUBSTITUTED INDOLIZINE DERIVATIVES, INHIBITORS OF FGFS, METHOD FOR MAKING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI AVENTIS (FR) 2005-09-07 EP disclosed
EP-1495023-A1 NOVEL 1,2,3-SUBSTITUTED INDOLIZINE DERIVATIVES, INHIBITORS OF FGFS, METHOD FOR MAKING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Sanofi-Aventis (FR) 2005-01-12 EP disclosed
WO-2003084956-A1 NOVEL 1,2,3-SUBSTITUTED INDOLIZINE DERIVATIVES, INHIBITORS OF FGFS, METHOD FOR MAKING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI-AVENTIS (FR) 2003-10-16 WO disclosed